In May, the Sendai District Court dismissed a suit against the government filed by two women who underwent forced sterilization under the now-defunct Eugenic Protections Law because the statute of limitations had expired. However, the judges said that the law, which allowed the government to prevent people with intellectual disabilities from reproducing, was unconstitutional. As a precedent, the ruling was significant because it recognized a woman's constitutional right to self-determination regarding pregnancy and childbirth. This aspect of the decision has since become a media topic of discussion about contraception. As pointed out in a Sept. 23 article in the Asahi Shimbun, Japan is behind the global curve when it comes to reproductive rights.
Boots has said it is "truly sorry" for its response to calls to cut the cost of one of its morning-after pills. The pharmaceutical company was criticised after telling the British Pregnancy Advisory Service (BPAS) it was avoiding "incentivising inappropriate use". It now says it is looking for cheaper alternatives to the Levonelle brand. The firm said it "sincerely" apologised for its "poor choice of words" over the emergency contraception pricing. The progestogen-based drug Levonelle costs £28.25 in Boots, with a non-branded equivalent priced at £26.75.
Another grant of almost $455,000 will be used to improve the telemedicine platform for Avera's eCARE program in those communities; and Roughly $362,000 awarded to Maury Regional Hospital in Tennessee to create a hub-and-spoke telemedicine network linking three hospitals in Missouri, three in Arkansas, two in Oklahoma and one in Kansas with Mercy Virtual in St. Louis. More than $390,000 awarded to Avera Health to expand a telehealth network providing specialist consults to 73 new sites in South Dakota, Minnesota, Iowa and Nebraska, serving some 635,000 patients. Another grant of almost $455,000 will be used to improve the telemedicine platform for Avera's eCARE program in those communities; and Roughly $362,000 awarded to Maury Regional Hospital in Tennessee to create a hub-and-spoke telemedicine network linking three hospitals in Missouri, three in Arkansas, two in Oklahoma and one in Kansas with Mercy Virtual in St. Louis.
WASHINGTON -- The Trump administration's new birth control rule is raising questions among some doctors and researchers, who say it overlooks known benefits of contraception while selectively citing data that raise doubts about effectiveness and safety. "This rule is listing things that are not scientifically validated, and in some cases things that are wrong, to try to justify a decision that is not in the best interests of women and society," said Dr. Hal Lawrence, CEO of the American Congress of Obstetricians and Gynecologists, a professional society representing women's health specialists. Two recently issued rules -- one addressing religious objections and the other, moral objections -- allow more employers to opt out of covering birth control as a preventive benefit for women under the Obama health care law. Although the regulations ultimately address matters of individual conscience and religious teaching, they also dive into medical research and scholarly studies on birth control. It's on the science that researchers are questioning the Trump administration.